About Atsena Therapeutics
Atsena Therapeutics is a private company based in Durham, North Carolina. It has reported $146,049,324 raised in four offerings on Form D since May 2020. Its chief executive is Patrick Ritschel.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 2025 | Apr 11, 2025 | $89,999,975of $150.0M target | 14 | $6.4M | EquityRule 506(b) | Form D ↗ |
| Aug 28, 2023 | Oct 2, 2023 | $24,474,387of $32.0M target | 10 | $2.4M | EquityRule 506(b) | Form D ↗ |
| Dec 15, 2020 | Dec 23, 2020 | $27,499,973of $55.0M target | 11 | $2.4M | Equity, Preferred stock can convert to underlying shares of Common StockRule 506(b) | Form D ↗ |
| Apr 24, 2020 | May 8, 2020 | $4,074,989of $8.1M target | 7 | $582K | Equity, Preferred Stock can convert to underlying shares of Common Stock.Rule 506(b) | Form D ↗ |
| Total, four offerings | $146,049,324 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Atsena Therapeutics's Form D filed Apr 11, 2025.
Earlier filings also listed Shannon Boye (director, last listed Oct 2023), Michael Dial (director, last listed Oct 2023), James Healy (director, last listed Oct 2023), Elizabeth Leiderman (executive officer, last listed Oct 2023), Sanford Boye (executive officer, last listed Dec 2020) and Benjamin Yerxa (director, last listed Dec 2020).